108 related articles for article (PubMed ID: 533991)
1. Residual marrow injury following cytotoxic drugs.
Trainor KJ; Seshadri RS; Morley AA
Leuk Res; 1979; 3(4):205-10. PubMed ID: 533991
[No Abstract] [Full Text] [Related]
2. The carcinogenic properties of some of the principal drugs used in clinical cancer chemotherapy.
Weisburger JH; Griswold DP; Prejean JD; Casey AE; Wood HB; Weisburger EK
Recent Results Cancer Res; 1975; (52):1-17. PubMed ID: 138176
[No Abstract] [Full Text] [Related]
3. Factors determining cell killing by chemotherapeutic agents in vivo. II. Melphalan, chlorambucil and nitrogen mustard.
van Putten LM; Lelieveld P
Eur J Cancer (1965); 1971 Feb; 7(1):11-6. PubMed ID: 5576726
[No Abstract] [Full Text] [Related]
4. Screening of cytotoxic drugs for residual bone marrow damage.
Trainor KJ; Morley AA
J Natl Cancer Inst; 1976 Dec; 57(6):1237-9. PubMed ID: 1003558
[TBL] [Abstract][Full Text] [Related]
5. 6-[Bis(2-chloroethyl)amino]-6-deoxygalactopyranose hydrochloride (C6-galactose mustard), a new alkylating agent with reduced bone marrow toxicity.
Schein PS; Green D; Dean SW; McPherson E
Cancer Res; 1987 Feb; 47(3):696-9. PubMed ID: 3802075
[TBL] [Abstract][Full Text] [Related]
6. Dose-survival curves of cis-platinum, melphalan, and velban in human granulocyte/macrophage progenitor cells.
Umbach GE; Singletary SE; Tomasovic B; Spitzer G; Hug V; Drewinko B
Int J Cell Cloning; 1984 Nov; 2(6):335-40. PubMed ID: 6542929
[TBL] [Abstract][Full Text] [Related]
7. The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L518Y lymphoblsts.
Goldenberg GJ
Cancer Res; 1975 Jul; 35(7):1687-92. PubMed ID: 1055634
[TBL] [Abstract][Full Text] [Related]
8. Cain's quinolinium (NSC 176319): protection of murine L1210 leukemia cells and bone marrow progenitor cells against mechlorethamine cytotoxicity and its application to combination chemotherapy.
Naujokaitis SA
Res Commun Chem Pathol Pharmacol; 1981 Oct; 34(1):97-104. PubMed ID: 7313308
[TBL] [Abstract][Full Text] [Related]
9. [Effects of bleeding on experimental hemotoxicity of chlorambucil].
Dolcino G; Ronco D; Massa G; Bogliolo G; Testa R; Pannacciulli I
Arch Maragliano Patol Clin; 1973; 29(2):149-52. PubMed ID: 4808340
[No Abstract] [Full Text] [Related]
10. Cytotoxic drugs and the granulopoietic system.
Lohrmann HP; Schreml W
Recent Results Cancer Res; 1982; 81():1-222. PubMed ID: 6173905
[No Abstract] [Full Text] [Related]
11. Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: protection from hematological and nonhematological toxicities.
Damia G; Komschlies KL; Futami H; Back T; Gruys ME; Longo DL; Keller JR; Ruscetti FW; Wiltrout RH
Cancer Res; 1992 Aug; 52(15):4082-9. PubMed ID: 1638519
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and bone marrow toxicity of aminoglucose mustard anticancer agents in mice.
Cantrell JE; Green D; Schein PS
Cancer Res; 1986 May; 46(5):2340-3. PubMed ID: 2938728
[TBL] [Abstract][Full Text] [Related]
13. Effects of estrogen on erythropoiesis and granuloid progenitor cell (CFU-C) proliferation in mice.
Adler SS; Trobough FE
J Lab Clin Med; 1978 Jun; 91(6):960-8. PubMed ID: 650060
[No Abstract] [Full Text] [Related]
14. Myeloprotective effect of diethyldithiocarbamate treatment following 1,3-bis(2-chloroethyl)-1-nitrosourea, adriamycin, or mitomycin C in mice.
Schmalbach TK; Borch RF
Cancer Res; 1989 May; 49(10):2574-7. PubMed ID: 2540902
[TBL] [Abstract][Full Text] [Related]
15. Toxic effects of benzene and benzene metabolites on granulopoietic stem cells and bone marrow cellularity in mice.
Tunek A; Olofsson T; Berlin M
Toxicol Appl Pharmacol; 1981 Jun; 59(1):149-56. PubMed ID: 7256752
[No Abstract] [Full Text] [Related]
16. Development of latent residual drug damage to the hematopoietic marrow during the subsequent growth of tumors.
Kovacs CJ; Johnke RM; Evans MJ; Emma DA; Hooker JL
Exp Hematol; 1986 Mar; 14(3):165-72. PubMed ID: 3948928
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 1-induced sequential myelorestoration: dynamic relation between granulopoiesis and progenitor cell recovery in myelosuppressed mice.
Ido M; Harada M; Furuichi H; Matsuoka N; Nakano K; Sohmura Y
Exp Hematol; 1992 Feb; 20(2):161-6. PubMed ID: 1371964
[TBL] [Abstract][Full Text] [Related]
18. Effect of preinduction of metallothionein synthesis on clastogenicity of anticancer drugs in mice.
Nakagawa I; Nishi E; Naganuma A; Imura N
Mutat Res; 1995 Sep; 348(1):37-43. PubMed ID: 7565913
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG).
Kuin A; Aalders M; Lamfers M; van Zuidam DJ; Essers M; Beijnen JH; Smets LA
Br J Cancer; 1999 Feb; 79(5-6):793-801. PubMed ID: 10070871
[TBL] [Abstract][Full Text] [Related]
20. [Targeting bone marrow with the help of polyalkylcyanoacrylate nanoparticles].
Gibaud S; Weingarten C; Andreux JP; Couvreur P
Ann Pharm Fr; 1999 Jul; 57(4):324-31. PubMed ID: 10472705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
